scholarly journals Takayasu's arteritis associated with crescentic glomerulonephritis

1987 ◽  
Vol 30 (4) ◽  
pp. 451-454 ◽  
Author(s):  
David B. Hellmann ◽  
Kenneth Hardy ◽  
Stan Lindenfeld ◽  
Ernest Ring
Keyword(s):  
Crescentic Glomerulonephritis ◽  
Takayasu’S Arteritis ◽  
Takayasu's Arteritis

Anticoagulants in Takayasu's Arteritis Associated with Crescentic Glomerulonephritis and Nephrotic Syndrome

Angiology ◽  
1998 ◽  
Vol 49 (1) ◽  
pp. 75-78 ◽  
Author(s):  
Masataka Iwane ◽  
Yasuko Nakamura ◽  
Ichiro Nishio ◽  
Mikio Arita
Keyword(s):  
Nephrotic Syndrome ◽  
Crescentic Glomerulonephritis ◽  
Takayasu’S Arteritis ◽  
Takayasu's Arteritis

Takayasu's Arteritis Coexisting with Wegener's Granulomatosis in a Teenager with Renal Insufficiency: Case Report

1999 ◽  
Vol 2 (4) ◽  
pp. 385-388 ◽  
Author(s):  
Carmen Mejia-Hernandez ◽  
Antonio Alvarez-Mendoza ◽  
Beatriz DeLeon-Bojorge
Keyword(s):  
Renal Insufficiency ◽  
Elevated Level ◽  
Wegener’S Granulomatosis ◽  
Crescentic Glomerulonephritis ◽  
Takayasu’S Arteritis ◽  
Wegener's Granulomatosis ◽  
Antineutrophil Cytoplasmic Antibodies ◽  
Infectious Agents ◽  
Takayasu's Arteritis ◽  
Severe Renal Insufficiency

A case of Wegener's granulomatosis (WG) coexisting with Takayasu's arteritis (TA) in a 12-year-old girl is presented. She presented with fulminant and severe renal insufficiency due to crescentic glomerulonephritis. At autopsy, aortic lesions of Takayasu's arteritis coexisted with pulmonary and renal findings of WG, and the patient's serum at autopsy had an elevated level of antineutrophil cytoplasmic antibodies (ANCA). Both forms of vasculitis have been thought to be triggered by infectious agents and it is postulated that this occurrence accounts for the coexistence of the two forms of vasculitis in this case.

Histological verification of non-specific aorta-arteritis (Takayasu's arteritis) using percutaneous transluminal atherectomy

VASA ◽  
2004 ◽  
Vol 33 (4) ◽  
pp. 247-251 ◽  
Author(s):  
Zeller ◽  
Koch ◽  
Frank ◽  
Bürgelin ◽  
Schwarzwälder ◽  
...  
Keyword(s):  
Clinical Diagnosis ◽  
Axillary Artery ◽  
Takayasu’S Arteritis ◽  
Giant Cells ◽  
Interventional Therapy ◽  
Takayasu's Arteritis ◽  
New Device ◽  
First Case ◽  
Anti Inflammatory ◽  
Percutaneous Transluminal

Diagnosis of non-specific aorto-arteritis (NSAA, Takaysu's arteritis) is typically based on clinical and investigational parameters. We report here about two patients with clinically suspected diagnosis of a Takayasu's arteritis already under anti-inflammatory therapy in whom percutaneous transluminal atherectomy of subclavian and axillary artery stenoses was performed to relief the patients from symptoms – intermittent dyspraxia of the arms – and to verify the clinical diagnosis by histology. In the first case aorto-arteritis could be histologically confirmed through the analysis of plaque material including media structures excised from the subclavian and axillary arteries using a new device for atherectomy. The biopsy showed diffuse inflammation and granulomatous lesions with giant cells typically for Takayasu's disease. In the second patient, biopsy showed no acute or chronic inflammatory signs but only atherosclerotic lesions. Percutaneous transluminal atherectomy is therefore not only an interventional but also a diagnostic tool and should be used in every case of interventional therapy of suspected aorto-arteritis to make the clinical diagnosis and as a major consequence the initiation of an aggressive anti-inflammatory medical therapy more reliable.

Transluminal Catheter angioplasty of abdominal aorta in Takayasu's arteritis

1988 ◽  
Vol 29 (5) ◽  
pp. 509-513 ◽  
Author(s):  
Z. M. Gu ◽  
G. Lin ◽  
J. R. Yi ◽  
J. M. Li ◽  
J. Zhou ◽  
...  
Keyword(s):  
Abdominal Aorta ◽  
Takayasu’S Arteritis ◽  
Takayasu's Arteritis

THE DIAGNOSE AND CLINICAL POLYMORPISM FEATURES OF TAKAYASU’S ARTERITIS

2020 ◽  
Vol 21 (2) ◽  
pp. 106-111
Author(s):  
N.S. SAMSONOV ◽  
◽  
S.A. USHAKOVA ◽  
O.Y. KHALIDULLINA ◽  
E.A. BASHTAKOVA ◽  
...  
Keyword(s):  
Takayasu’S Arteritis ◽  
Takayasu's Arteritis

HADS-depression score is a mediator for illness perception and daily life impairment in Takayasu’s arteritis

2021 ◽  
Author(s):  
Simay Erdal ◽  
Banu Nalbantoğlu ◽  
Mert Berke Gür ◽  
Murathan Yıldırım ◽  
Alperen Kılıçarslan ◽  
...  
Keyword(s):  
Daily Life ◽  
Takayasu’S Arteritis ◽  
Illness Perception ◽  
Depression Score ◽  
Takayasu's Arteritis

scholarly journals Tocilizumab in refractory Caucasian Takayasu’s arteritis: a multicenter study of 54 patients and literature review

2021 ◽  
Vol 13 ◽  
pp. 1759720X2110209
Author(s):  
Diana Prieto-Peña ◽  
Pilar Bernabeu ◽  
Paloma Vela ◽  
Javier Narváez ◽  
Jesús C. Fernández-López ◽  
...  
Keyword(s):  
Adverse Events ◽  
Multicenter Study ◽  
Takayasu’S Arteritis ◽  
Imaging Techniques ◽  
Takayasu's Arteritis ◽  
Prednisone Dose ◽  
Reactive Protein ◽  
Caucasian Origin ◽  
Caucasian Patients ◽  
Sparing Effect

Objective: To assess the efficacy and safety of tocilizumab (TCZ) in Caucasian patients with refractory Takayasu’s arteritis (TAK) in clinical practice. Methods: A multicenter study of Caucasian patients with refractory TAK who received TCZ. The outcome variables were remission, glucocorticoid-sparing effect, improvement in imaging techniques, and adverse events. A comparative study between patients who received TCZ as monotherapy (TCZMONO) and combined with conventional disease modifying anti-rheumatic drugs (cDMARDs) (TCZCOMBO) was performed. Results: The study comprised 54 patients (46 women/8 men) with a median [interquartile range (IQR)] age of 42.0 (32.5–50.5) years. TCZ was started after a median (IQR) of 12.0 (3.0–31.5) months since TAK diagnosis. Remission was achieved in 12/54 (22.2%), 19/49 (38.8%), 23/44 (52.3%), and 27/36 (75%) patients at 1, 3, 6, and 12 months, respectively. The prednisone dose was reduced from 30.0 mg/day (12.5–50.0) to 5.0 (0.0–5.6) mg/day at 12 months. An improvement in imaging findings was reported in 28 (73.7%) patients after a median (IQR) of 9.0 (6.0–14.0) months. Twenty-three (42.6%) patients were on TCZMONO and 31 (57.4%) on TCZCOMBO: MTX ( n = 28), cyclosporine A ( n = 2), azathioprine ( n = 1). Patients on TCZCOMBO were younger [38.0 (27.0–46.0) versus 45.0 (38.0–57.0)] years; difference (diff) [95% confidence interval (CI) = -7.0 (-17.9, -0.56] with a trend to longer TAK duration [21.0 (6.0–38.0) versus 6.0 (1.0–23.0)] months; diff 95% CI = 15 (-8.9, 35.5), and higher c-reactive protein [2.4 (0.7–5.6) versus 1.3 (0.3–3.3)] mg/dl; diff 95% CI = 1.1 (-0.26, 2.99). Despite these differences, similar outcomes were observed in both groups (log rank p = 0.862). Relevant adverse events were reported in six (11.1%) patients, but only three developed severe events that required TCZ withdrawal. Conclusion: TCZ in monotherapy, or combined with cDMARDs, is effective and safe in patients with refractory TAK of Caucasian origin.

Sign in / Sign up

Export Citation Format

Share Document